User login
BALTIMORE – Methods to prevent and treat migraines are lacking, but monoclonal antibodies and the calcitonin receptor system are showing promise, according to Dr. Peter Goadsby of the University of California, San Francisco.
“It’s an awful mishmash of things we have to offer,” Dr. Goadsby said at the annual meeting of the American Neurological Association. However, data presented at the meeting suggest that new options may be on the horizon.
In an interview at the meeting, Dr. Goadsby explained details of several studies that showed dramatic results, and the “tantalizing” implications for patients.
BALTIMORE – Methods to prevent and treat migraines are lacking, but monoclonal antibodies and the calcitonin receptor system are showing promise, according to Dr. Peter Goadsby of the University of California, San Francisco.
“It’s an awful mishmash of things we have to offer,” Dr. Goadsby said at the annual meeting of the American Neurological Association. However, data presented at the meeting suggest that new options may be on the horizon.
In an interview at the meeting, Dr. Goadsby explained details of several studies that showed dramatic results, and the “tantalizing” implications for patients.
BALTIMORE – Methods to prevent and treat migraines are lacking, but monoclonal antibodies and the calcitonin receptor system are showing promise, according to Dr. Peter Goadsby of the University of California, San Francisco.
“It’s an awful mishmash of things we have to offer,” Dr. Goadsby said at the annual meeting of the American Neurological Association. However, data presented at the meeting suggest that new options may be on the horizon.
In an interview at the meeting, Dr. Goadsby explained details of several studies that showed dramatic results, and the “tantalizing” implications for patients.
AT ANA 2014
